Market LIVE
Published markets; coverage varies by country
Product profile · United States

BUTRANS

 ·  Patent Litigation & Settlement History ↓

IngredientBUPRENORPHINE
Application typeNDA
Application021306
Product005
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
Strength7.5MCG/HR
Approval date2014-06-30
Marketing statusPrescription
Status event—
ApplicantKNOA PHARMA
Product source

Current GenericRadar decision

Year2020
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2020-04-14
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2020-04-14
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211586 / 002FINAL_APPROVAL · FINAL_APPROVED2020-04-14—AMNEAL PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210162 / 002FINAL_APPROVAL · FINAL_APPROVED2021-05-03—MYLAN TECHNOLOGIES INC A VIATRIS CONEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
204937 / 005FINAL_APPROVAL · FINAL_APPROVED2021-06-29—WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210272 / 002FINAL_APPROVAL · FINAL_APPROVED2021-09-23—DIFGEN PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207490 / 005FINAL_APPROVAL · FINAL_APPROVED2023-03-21—STRIDES PHARMA INTERNATIONAL AGNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 5 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211586 / 002AMNEAL PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2020-04-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210162 / 002MYLAN TECHNOLOGIES INC A VIATRIS COFINAL_APPROVAL · FINAL_APPROVED2021-05-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
204937 / 005WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2021-06-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210272 / 002DIFGEN PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2021-09-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207490 / 005STRIDES PHARMA INTERNATIONAL AGFINAL_APPROVAL · FINAL_APPROVED2023-03-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2020-04-14TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.